Drug Trial Radar · NCT05600062
Influence of NEP Inhibition on Vascular Leak and Inflammation (NEPi-INFLAMMATION)
Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Mar 21, 2023
Primary completion
Feb 1, 2026
Study completion Jun 15, 2026
Sponsor
- Lead sponsor
- Queen Mary University of LondonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Medical Research Council
- First posted
- Oct 31, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Acute Respiratory Distress Syndrome (ARDS) is a severe type of lung injury that affects 10% of patients admitted to Intensive Care Units worldwide, with an unacceptably high mortality of up to 48% in those with the most severe form of the condition. It is a complex and poorly understood syndrome that results in progressive failure of the lungs. Crucially, the inflamed lungs allow fluid to leak from the circulation into the airspace, so that patients' lungs fill with fluid - "drowning from the inside". As this condition progresses, the patient typically requires increasing amounts of oxygen and eventually, support from a ventilator. To date, there are no effective treatments for ARDS that can limit, stop or repair this process. This research study is aiming to look at a naturally occurring substance produced by blood vessels, C-type natriuretic peptide (CNP). The investigators have evidence suggesting that CNP plays a role in maintaining the barrier provided by blood vessels that stops fluid leaking out into tissues. This is based on various studies done on CNP by the investigators research group that have established its widespread role in maintaining cells that line blood vessels and play a vital role in lungs' barrier function: the endothelium. CNP is broken down in part by an enzyme called Neutral endopeptidase and therefore, drugs that inhibit this enzyme would result in increased CNP concentration and activity. If CNP does in fact strengthen the lungs' endothelial barrier, then this class of drug may benefit patients with ARDS. The aim of this experimental medicine study is to assess the effect of using the licensed NEP inhibitor Racecadotril, in a well-established, safe model of inflammation-induced skin blisters in healthy human volunteers to determine primarily whether the fluid accumulation i.e. leak, in these blisters is reduced by treatment with this drug.
Conditions
- Acute Respiratory Distress Syndrome
Interventions
Racecadotril 100 milligram (MG) Oral CapsuleDrug
Licensed NEP inhibitor
PlaceboDrug
Placebo capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Powered unpaired inter-patient comparison of change in blister fluid volume following Racecadotril or placebo administration.Time frame: 24 hours after application of cantharidin
- Powered paired intra-patient comparison of change in blister fluid volume following Racecadotril or placebo admininstration.Time frame: 24 hours after application of cantharidin
Locations
1 site in 1 country. Site status is shown where the registry gives one.
William Harvey Research Institute- Heart Centre
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.